hat
ki ka ogmante risk anpil nan evènman twonpik tankou anbolis ak konjesyon serebral. Kontrèman ak anpil lòt AAS, Stanolone pa aromatize e li pa gen okenn risk nan efè segondè estwojèn tankou gynecomastia, retansyon likid, oswa èdèm.Anplis de sa, kòm li se pa yon 17a -alkilated AAS ak administre parenteral, Stanolone pa gen okenn risk pou hepatotoxicity.
eng
which can greatly increase the risk of thrombic events such as embolism and stroke.Unlike many other AAS, Stanolone is not aromatized and has no risk of estrogenic side effects like gynecomastia, fluid retention, or edema.In addition, as it is not a 17α-alkylated AAS and is administered parenterally, Stanolone has no risk of hepatotoxicity.